someone is buying them up, page-6

You may be right.

On the other hand, you may very well be wrong.

If present experimental work gives poor results, I would expect the company to be wound up in the near term with a cash distribution that would not likely exceed 4.5 cents per share.

On the other hand, if the oral insulin is shown to be effective in pigs or a primate, then don't expect an early demise. The next few months should be determinative.